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Abstract
Fibrosis in systemic sclerosis (SSc), a complex polygenic disease associated with autoimmunity and proliferative/
obliterative vasculopathy, shares pathobiologic features in common with other fibrosing illnesses, but also has
distinguishing characteristics. Fibroblast activation induced by transforming growth factor-b (TGF-b), Wnts and
innate immune receptors, along with oxidative stress and reactive oxygen species (ROS) are implicated in
pathogenesis. On the other hand, the roles of endothelial-mesenchymal differentiation and bone marrow-derived
fibrocytes remain to be established. Fibrotic responses are modulated by transcriptional activators and cofactors,
epigenetic factors, and microRNAs that can amplify or inhibit ligand-induced signaling. The nuclear orphan
receptor PPAR-g appears to be important in governing the duration and intensity of fibroblast activation and
mesenchymal progenitor cell differentiation, and defects in PPAR-g expression or function in SSc may underlie the
uncontrolled progression of fibrosis. Identifying the perturbations in signaling pathways and cellular differentiation
programs responsible for tissue damage and fibrosis in SSc allows their selective targeting using novel compounds,
or by innovative uses of already-approved drugs (drug repurposing).
Introduction
Systemic sclerosis (SSc) is serious chronic fibrosing
disease with high mortality without any effective ther-
apy. Progressive fibrosis in the lungs, heart, kidneys
and other organ leads to their dysfunction and even-
tual failure. The inability to identify appropriate
patients for treatment with existing or novel targeted
disease-modifying therapies is due to multiple factors:
1) complex nature of SSc, with concomitant vascular
injury, autoimmunity, inflammation and fibrosis; 2)
lack of bona fide animal models of disease; 3) poorly
understood genetic and environmental risk factors; and
4) significant patient-to-patient clinical heterogeneity
in terms of disease course and outcomes. This over-
view focuses on the pathobiological features that SSc
shares with other fibrosing conditions, and some that
a r eu n i q u et oS S c .
Fibroblast activation in SSc
Fibroblasts explanted from the lesional skin of SSc patients
synthesize increased amounts of collagen and fibronectin
in vitro [1,2]. Moreover, SSc fibroblasts show constitutive
production of cytokines and chemokines; and spontaneous
myofibroblast transdifferentiation [3]. Whether these phe-
notypic features reflect cell-autonomous perturbations of
intracellular signaling molecules and pathways due to
genetic or epigenetic alterations, or reflect paracrine/auto-
crine fibroblast activation triggered by extracellular cues
[4,5] (Table 1 and 2) remains unanswered.
Cell types and cell fate switching in fibrosis
The fibroblast is the proximal effector cell directly
responsible for fibrosis. However, recent studies indicate
that bone marrow-derived mesenchymal progenitors
such as fibrocytes and monocytes might traffic to
damaged tissue and undergo in situ differentiation into
activated fibroblasts and myofibroblasts. Non-fibroblastic
cell lineages (such as epithelial or endothelial cells or
adipocytes) can also differentiate into fibroblasts and
myofibroblasts via processes involving Notch, Snail, Slug
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mote the transition of precursor and non-fibroblastic
cell types toward an activated myofibroblast phenotype,
whereas PPAR-g promotes the maintenance of cellular
quiescence. To date, no convincing evidence has
emerged to implicate cellular plasticity in the pathogen-
esis of fibrosis in SSc.
Persistent fibrosis: innate immune recognition signaling
via TLRs
Innate immune recognition signaling via toll-like receptors
(TLRs) appears to play an important role in the persistent
fibrotic response in SSc. The ability to recognize patho-
gen-associated molecular patterns via pattern recognition
receptors (PRRs) is a critical aspect of the host ability to
respond to foreign microorganisms [6]. We have demon-
strated that TLR3 and TLR4 are expressed in normal
fibroblasts and transduce signals from lipopolysaccharide
( L P S )a sw e l la se n d o g e n o u sT L Rl i g a n d s ,t h es o - c a l l e d
damage-associated molecular pattern (DAMPs) such as
polyinosinic:polycytidylic acid and matrix components
such as hyaluronic acid, and fibronectin-EDA (Fn-EDA)
[7,8]. In the liver, TLR4 activated by LPS plays a critical
role in fibrosis, with suppression of BAMBI and sensitiza-
tion to TGF-b as the underlying mechanisms [9]. We
speculate that in SSc tissue injury, exacerbated by hypoxia
and accumulation of reactive oxygen species (ROS), up-
regulate fibroblast TLR4 expression and/or activity on
mesenchymal stromal cells, contributing to TLR-mediated
amplification of TGF-b signaling. Moreover, oxidative
damage and tissue remodeling generating DAMPs such as
low molecular weight hyaluronan degradation products,
Fn-EDA, Tenascin C, and biglycan; cellular stress proteins
such as HMGB1 and Hsp60; and nucleic acids and
immune complexes, each of which might activate fibro-
blasts via TLRs engagement. In this way, the accumulation
of tissue damage-associated endogenous TLR ligands serve
as a danger signals that perpetuate fibroblasts activation.
We speculate that DAMP-induced TLR signaling might
serve as the critical “switch” that, when turned on, con-
verts a self-limited tissue repair process into one of persis-
tent and unchecked fibroblasts activation resulting in
progressive fibrosis in SSc. This concept is illustrated in
Figure 1.
Fibroblast activation
Transforming growth factor-b is the pre-eminent signal
for connective tissue synthesis, and is considered as a
“core pathway” in both normal wound healing and patho-
logical fibrosis. Microarray-based analysis of genome-
wide changes in gene expression has shown that a subset
of SSc patients with aggressive disease show evidence of
activation of TGF-b-dependent signaling pathways in the
lesional skin [10-12].
Table 1 Intracellular signal mediators showing aberrant expression in SSc
Molecule Increased expression/activity Decreased expression/activity
Egr-1, Egr-2 ⇑
Sp1 ⇑
p300/CBP ⇑
Fli-1 ⇓
Smad7 ⇓
Ski/Sno ⇓
Nab2 ⇓
PTEN ⇓
PPAR-gamma ⇓
microRNA29 ⇓
Table 2 Extrinsic mediators of fibroblast activity
potentially implicated in SSc
Cytokines
TGF-b
IL-4
IL-13
IL-17
IL-33
Growth factors, peptides and bioactive lipids
Wnt family (Wnt3a, Wnt10b, others)
CTGF (matricellular protein)
PDGF
IGFBP-5
Endothelin-1
Adenosine
Lysophosphatidic acid (LPA)
Prostaglandin F
Chemokines
CXCL12
MCP-1
Autoantibodies
Antibody to Topo I
Anti-fibroblast antibody
Anti-PDGF antibody
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Egr-1
In normal fibroblasts, TGF-b induces Smad-independent
activation of c-Abl, a Src family non-receptor tyrosine
kinase implicated in chronic myelogenous leukemia
(CML) [13-15]. Endogenous c-Abl is required for the pro-
fibrotic responses induced by TGF-b in vitro. Imatinib, a
small molecule inhibitor of c-Abl kinase used for the treat-
ment of CML and gastrointestinal stromal tumors,
blocked the stimulation of collagen synthesis, fibroblast
proliferation and myofibroblast transdifferentiation elicited
by TGF-b. Moreover, imatinib suppressed the constitu-
tively elevated collagen gene expression in SSc fibroblasts
(Hinchcliff et al, manuscript submitted). In vivo, imatinib
attenuated the severity of lung and skin fibrosis induced
by bleomycin in mice [13,15]. It is noteworthy that imati-
nib blocks signaling via receptor for PDGF. An important
downstream target of c-Abl appears to be Egr-1, a prototy-
pical member of zinc finger transcription factors. Egr-1
expression is typically induced at sites of injury by cyto-
kines, lipids and mechanical injury. Egr-1 is implicated in
cell proliferation, differentiation and survival [16]. TGF-b
was shown to induce Egr-1 expression in normal dermal
fibroblasts [17,18]. Fibroblasts lacking Egr-1 showed loss
of collagen stimulation in response to TGF-b, identifying
Egr-1 as a novel downstream mediator of profibrotic
TGF-b responses. Moreover, Egr-1 induces the production
of TGF-b and TGF-b receptors, and also stimulates the
coactivator and histone acetyl transferase p300, thereby
greatly amplifying TGF-b-induced cellular responses [17]
and Ghosh AK et al, MS submitted). Expression of the
oxidase enzyme Nox4, responsible for ROS generation in
TGF-b-stimulated fibroblasts, is directly stimulated by
Egr-1[19]. Lesional skin biopsies from SSc patients shows
increased Egr-1 expression and activity. Furthermore,
mice lacking Egr-1 have markedly attenuated fibrotic
response to bleomycin in vivo [20]. Egr-1 thus emerges
potent fibrogenic mediator in the pathogenesis of SSc.
Aberrant activation of the developmental Wnt-b-catenin
program in SSc
The Wnts constitute a large family of secreted signaling
glycoproteins with key roles in embryonic development
and organogenesis. In contrast to embryogenesis, where
the Wnt pathway is active, in adults Wnt signaling is nor-
mally tightly regulated. Canonical Wnt signaling is
initiated by ligand binding to Frizzled (FZD) and Low-
density lipoprotein receptor-related protein (LRP) surface
receptors, stabilizing cytosolic b-catenin. In the absence
of ligand, b-catenin is phosphorylated by glycogen
synthetase kinase 3-b (GSK3-b), leading to its ubiquitina-
tion and proteasomal degradation [21]. In Wnt-stimu-
lated fibroblasts, the FZD receptor inhibits GSK-3b
activity and blocks b-catenin degradation. b-catenin con-
sequently translocates into the nucleus where is regulates
target gene transcription via TCF/LEF binding. Expres-
sion of many Wnt target genes is regulated in a cell type-
specific manner [22,23]. Genomewide profiling reveals
elevated Wnt/b-catenin signature in patients with pul-
monary fibrosis [24-26] and SSc [11,27]. These observa-
tions are further confirmed by detection of constitutive
GSK-3b phosphorylation and nuclear b-catenin localiza-
tion in fibrotic lesion [25,26,28] We found constitutive
Wnt-b-catenin activation in the lungs of patients with
SSc-associated pulmonary fibrosis [29] and in lesional
skin from dcSSc [30]. The source of Wnt ligand, and the
triggers for aberrant Wnt signaling are currently
unknown. In light of the ability of canonical Wnt path-
way to stimulate fibroblast activation and mesenchymal
progenitor cell differentiation [28,30], and the association
of transgenic Wnt10b expression with scleroderma-like
skin fibrosis and subcutaneous lipoatrophy in the mouse
[31], hyperactivation of canonical Wnt signaling in SSc
skin biopsies, while suppressing adipogenesis, aberrant
Wnt signaling is likely to be important in the pathogen-
esis of SSc, and is an interesting potential target for
therapy.
Bioactive lipids
Certain prostanoids inhibit fibrotic responses and tissue
remodeling through a variety of mechanisms [32],
whereas prostaglandin F (PGF2a) is elevated in IPF, and
stimulates collagen production and fibroblast prolifera-
tion [33]. Lysophosphatidic acid (LPA), generated from
membrane phospholipids via hydrolysis, induces fibro-
blast chemotaxis and CTGF production [34]. Mice with
targeted deletion of LPA1 are protected from bleomycin-
induced lung fibrosis. A recent study indicates that LPA
induces avb6-mediated TGF-b activation in epithelial
cells, contributing to sustained autocrine TGF-b signaling
Figure 1 Vicious cycle of FIBROSIS. Innate immune signaling
alters self-limited repair into sustained fibrogenic process. Following
injury, fibroblasts undergo a regulated activation. Once repair has
been accomplished, tissue regeneration is complete. Prolonged
injury leads to damage, causes activation of toll like receptors and
sustained fibroblast activation culminating in excessive fibrogenesis.
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fibrosis of the lungs, kidneys and liver, and the availability
of small molecule LPA1 makes this approach particularly
appealing.
Peroxisome proliferator-activated receptor-g: intrinsic
negative regulation of fibroblast activation and
differentiation
The nuclear orphan receptor peroxisome proliferator-
activated receptor gamma (PPAR-g) modulates TGF-b
signaling and mesenchymal cell plasticity. Naturally
occurring PPAR-g ligands including prostanoids such as
15d-prostaglandin J2 (15d-PGJ2)d r i v en u c l e a rP P A R - g
accumulation and DNA binding. Rosiglitazone and other
members of the thiazolidinedione class of insulin-sensi-
tizing drugs are synthetic PPAR-g agonists used in type 2
diabetes. PPAR-g is involved in energy metabolism, adi-
pogenesis, bone and vascular biology and immune
responses, and its abnormalities have been linked to lipo-
dystrophy, atherosclerosis, pulmonary hypertension, can-
cer, obesity and inflammation.
Recent studies have revealed an entirely novel function
for PPAR-g in connective tissue homeostasis and matrix
remodeling as a cell-intrinsic anti-fibrotic pathway. In nor-
mal fibroblasts, activation with either natural (15d-PGJ2)
or synthetic (rosiglitazone) PPAR-g ligands resulted in
abrogation of TGF-b-induced collagen production and
Smad3-dependent transcriptional responses [36]. Subse-
quent studies showed that PPAR-g blocked histone acetyl
transferase p300 recruitment due to competition for limit-
ing amounts of this indispensable Smad3 coactivator
(squelching), resulting in inhibition of Smad-dependent
transcriptional responses [37,38]. Moreover, PPAR-g
blocks the activation function of Egr-1 [39]. Incubation of
TGF-b-stimulated alveolar epithelial cells with PPAR-g
ligands prevented epithelial to mesenchymal transition
(EMT) and the associated suppression of E-cadherin levels
[40]. PPAR-g plays a fundamental role in regulating
mesenchymal cell lineage fate determination and can shift
progenitor cell differentiation along fibrogenic or non-
fibrogenic pathways.
Impaired PPAR-g in fibrosis and SSc: role in pathogenesis
Mouse studies have demonstrate that fibroblast-specific
gene targeting of PPAR-g resulted in exaggerated skin
fibrosis in bleomycin-treated mice [41], and PPAR-g dele-
tion targeted to follicular stem cells was associated with
scarring alopecia [42]. On the other hand, rosiglitazone
attenuated bleomycin-induced dermal fibrosis via induc-
tion of PPAR-g signaling [39]. Reduced PPAR-g expression
or function is associated with various forms of fibrosis in
vivo which may account for the predictable association of
fibrosis with subcutaneous and visceral lipoatrophy.
Remarkably, the process of aging itself is associated with
declining PPAR-g expression [43].
PPAR-g expression and activity are impaired in the
lesional skin in SSc [44]. Furthermore, PPAR-g expression
is inversely correlated with TGF-b signaling. Aberrant
expression or activity of profibrotic cues such as TGF-b
and Wnts might account for reduced PPAR-g function,
which in turn contributes to the progression of fibrosis
[45]. Together, these studies findings implicate defective
expression and function of PPAR-g in SSc, and raise the
possibility that activating PPAR-g using ligand agonists
such as the thiazolidenediones, novel non-agonist ligands,
or the triterpenoid CDDO, might be novel therapeutic
approaches.
Conclusion
Cell-intrinsic alterations in SSc fibroblasts including
deregulated TGF-b and Wnt signaling, altered expression
or function of c-Abl and Egr-1; persistent TLR activation
by DAMPs, hypoxia and mechanical forces and a func-
tional deficiency of endogenous repressors of fibroblast
differentiation and collagen production such as PPAR-g
and microRNAs, contribute to persistent biosynthetic
and mechanical activity, and progressive fibrosis [46].
The roles of progenitor cell differentiation and cellular
transitions in the development of SSc fibrosis and the
molecular factors regulatory processes remain to be
defined in SSc. The entire repertoire of molecular path-
ways contributing to fibroblasts activation and progres-
sive fibroproliferation needs to be annotated. Emerging
cellular and molecular targets provide a plethora of
appealing opportunities for therapy, as well as for the dis-
covery and validation of pathogenesis-based biomarkers
for clinical studies. We believe that these advances pre-
sage rapid research progress toward improved outcome
for management of patients with SSc.
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